RxDoctor Payments Data

Joseluis Jimenez, MD

Family Medicine · Germantown, MDNPI 1659422541

Payments from drug & device makers

$2,971in general payments, 2019–2025

Across 151 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$713
  • AstraZeneca$317
  • Merck$249
  • AbbVie$247
  • Amgen$201
  • Daiichi Sankyo Inc.$160
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,971 in reported general payments places this provider in the 80th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$75,537
Medicare patients
165
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$86,809
Janumet XrSitagliptin Phos/Metformin Hcl46$58,042
JanuviaSitagliptin Phosphate31$45,783
LinzessLinaclotide39$43,642
EliquisApixaban21$32,338
RybelsusSemaglutide12$30,689
TrulicityDulaglutide19$27,467
MyrbetriqMirabegron17$20,800
XareltoRivaroxaban12$19,199
FarxigaDapagliflozin Propanediol11$17,704
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide110$3,677
Rosuvastatin Calcium203$3,256
Diclofenac Sodium51$3,185
Duloxetine Hcl27$3,079
Metoprolol Succinate169$1,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet Xr, Januvia$249$103,82577 claims
Boehringer IngelheimJardiance$126$86,80964 claims
AbbVieLinzess$247$43,64239 claims
PfizerEliquis$136$32,33821 claims
Novo NordiskRybelsus$713$30,68912 claims
Lilly USA, LLCTrulicity$148$27,46719 claims
Astellas Pharma US IncMyrbetriq$99$20,80017 claims
Johnson & JohnsonXarelto$54$19,19912 claims
AstraZenecaFarxiga$317$17,70411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Germantown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →